Over 60 million blood and plasma donations are tested on Roche nucleic acid testing systems each day.1 From launching the first nucleic acid testing assays for blood screening, Roche has consistently remained at the forefront of keeping the blood supply safe through active surveillance of emerging infections and rapid development of screening solutions.
Roche nucleic acid testing instruments, assays, and reagents have been developed using the gold standard real-time Polymerase Chain Reaction (PCR) technology, a very sensitive technology that detects DNA and RNA molecules of infectious agents such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) at an early stage of an infection. Easily integrated into pre- and post-analytic solutions, our instruments enable donor screening facilities to automate operations, boost throughput, and achieve quicker turnaround times, leading to greater overall workflow efficiency.
Roche's state-of-the-art nucleic acid testing assays provide comprehensive genotype coverage and excellent sensitivity, working together with analyzers that provide efficient workflows and deliver fast results. Roche’s leading molecular diagnostic solutions provide predictable operational outcomes for laboratories and help reduce the risk of disease transmission and adverse health effects in patients.
Ensure the highest level of blood safety screening and testing with:
High-quality assay management and analysis, including:
Consistent, accurate and reliable testing solutions leveraging the benefits of:
A comprehensive NAT menu for blood and plasma screening, including:
*Products of the Roche Blood Safety Solutions portfolio are not commercially available in all regions. Please contact your local Roche representative regarding availability. In the US, pre and post analytics are standalone solutions.
**cobas® DPX is an in-process test for plasma intended for further manufacture.
References:
